bluuebunny/crossref_metadata_2025_split huggingface dataset:
Habitats change habits: How Garden Dormice cope with different environments in Germany
Authors: Lang Johannes , Battermann Julia-Marie , Sommer Franziska , Waldinger Silvia , Wuttke Mona , Meinig Holger , Famira-Parcsetich Eva Marie , Büchner Sven 
Published: April 2022

The Garden Dormouse is currently disappearing from parts of its range. While its population is declining in many parts of Germany including forest habitats in low mountain ranges, a stable occurrence is found in some cities. A radiotelemetry study was performed in the spruce forests of the Harz National Park (mountains) and the city of Wiesbaden to compare space and habitat use, and the structure and use of daytime nest sites (DNS) used for rest.
In total, eight individuals (5 males, 3 females) were tracked between May and September 2021. They used smaller home ranges in the city (MCP100: 2.39 ± 1.34 ha; n = 4) than in the forest (MCP100: 4.56 ± 3.13 ha; n = 4). At night, the animals used structures offering protection from predators and providing food like wide hedges in the city and rock crevices and berry bushes in the forest.
The animals were located in a DNS a total of 133 times, and one to ten different DNS per animal were identified. They were situated in structures providing a high degree of protection from predators and also had consistent temperatures (e.g. rock crevices , deadwood piles , hedges, vines on buildings, nest boxes, and buildings). While females rarely changed their DNS, males used several of them.
Recommended conservation measures for Garden Dormice include raising public awareness and also the protection and promotion of facade greening, hedges and old buildings in urban areas. A dense rocky cover, as well as a well-developed shrub layer with raspberry bushes are valuable in spruce woodlands .
A 24-year investigation of the reproductive ecology of the Edible Dormouse (Glis glis)
Authors: Brooks Sarah , Trout Roger , Hill Davina 
Published: April 2022

The Edible Dormouse is a non-native rodent introduced to the Chilterns, UK, in 1902. It shows extreme annual variation in breeding; either having one litter per year or, in some years, failing to breed at all. Despite this slow reproductive rate compared to other rodents, its population is increasing, and has spread beyond the anticipated landscape barriers. Communal nesting is sometimes observed. This study aims to characterise the reproduction parameters over time, including from communal breeding.
Based on a population of &gt;11,000 PIT-tagged individuals, 600 litters and 4000 nestlings at our Chilterns study site over 24 years, we show the best fit of the number of new-borns is an increasing exponential. Monthly weight of nestlings also increased over the 24 years, while annual reproduction rate, litter size and nestling growth rates remained unchanged. Litter size decreased from 6.6 new-borns in August to 4.3 in October, indicating an average death rate of 37% in the first two months of life. Preliminary analysis suggests a small decrease in death rate over the years. Average growth rate of nestlings was c.100% of birth weight per week in their first month, but then slowed. We also examined evidence of kinship between nest sharers and investigated whether this, or communal breeding in general, promotes offspring survival. Our results will provide a deeper insight into the factors that drive the reproductive success of this invasive species and enable investigation of the effect of climatic variables on the number, survival and growth rate of nestlings.
Protecting local populations of Hazel Dormice (Muscardinus avellanarius) by translocation: a long-term case study from North Rhine-Westphalia (Germany)
Authors: Höcker Lisa , Weiß Katja , Dietz Markus 
Published: April 2022

As part of the mitigation measures adopted in the context of preparatory clearcutting for surface mining, Hazel Dormice have been translocated since 2011. The project is situated in the geographical region of Lower Rhine Basin (North Rhine-Westphalia, Germany). To date, Hazel Dormice have been translocated from an old-growth deciduous forest to four other sites. Three release sites are re-cultivation areas which were planted with trees and shrubs roughly 10 to 30 years ago. The other release site is an old-growth deciduous forest with a well-developed understory. Nest boxes were placed in the source forest and checked between April and October. Any dormice that were found were individually marked and released, inside their nest boxes, at the new sites. Two or three additional nest boxes were placed within the surroundings of each translocated box.
Between 2011 and 2018 we translocated 1,840 individuals. We verify the success of translocation by monitoring the release sites in June and September of the first, second, fifth and eighth year after translocation. Additionally, a sample of 200 nest boxes were checked each month between April and October for five years. Finally, we examined groups of nest boxes shortly after translocation to gather information on the translocated animals immediately after release. Individual records reveals that translocation can be a successful conservation measure to secure local populations if their former habitat is damaged.
A new species of the genus Sweltsa Ricker, 1943 (Plecoptera, Chloroperlidae) from Guizhou Province, China
Authors: Rehman Abdur , Huo Qing-Bo , Du Yu-Zhou 
Published: April 2022

Sweltsa is a genus of green stoneflies in the family Chloroperlidae and is distributed throughout the Nearctic and East Palaearctic Regions. As they are sensitive to pollutants, they are often used as an indicator species for determining the quality of water bodies. There are around 57 species of this genus worldwide and 11 of those have been identified from China.
A new species of the Alloperlini genus Sweltsa Ricker, 1943, Sweltsa ligula Rehman, Huo &amp; Du sp. n. is described from Kuankuoshui National Natural Reserve, Suiyang County, Guizhou Province, southwest China. This is the first report of the family Chloroperlidae from Guizhou Province. Diagnosis, description of male, female and nymph, illustration of terminalia and similarities with closely-related species are provided and discussed.
Baseline Disease Activity Predicts Achievement of cDAPSA Treatment Targets With Apremilast: Phase III Results in DMARD-naïve Patients With Psoriatic Arthritis
Authors: Mease Philip J. , Kavanaugh Arthur , Ogdie Alexis , Wells Alvin F. , Bergman Martin , Gladman Dafna D. , Richter Sven , Teng Lichen , Jardon Shauna , Smolen Josef S. 
Published: April 2022

Objective.The probability of achieving Clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA) treatment targets (remission [REM], low disease activity [LDA]) was evaluated following apremilast monotherapy in disease-modifying antirheumatic drug (DMARD)-naïve patients with psoriatic arthritis (PsA) based on baseline disease activity.Methods.This post hoc probability analysis of PALACE 4, a phase III, multicenter, randomized, placebo-controlled study, evaluated shifting across cDAPSA categories from baseline to week 52 and included DMARD-naïve patients receiving apremilast 30 mg BID with available baseline cDAPSA data. Changes in articular/extraarticular manifestations were evaluated in patients with week 52 cDAPSA components. cDAPSA treatment target achievement was assessed in a subgroup with baseline extraarticular PsA manifestations (skin involvement, enthesitis, dactylitis).Results.Of 175 apremilast-treated patients in the probability analysis, 66.3% were in high disease activity (HDA) and 31.4% in moderate disease activity (ModDA) at baseline. Approximately twice as many patients in ModDA at baseline reached REM/LDA at week 52 vs those in HDA (61.7% vs 28.2%). Achieving cDAPSA treatment targets was associated with reductions in articular (swollen/tender joints) and extraarticular (skin involvement, enthesitis, dactylitis, functional disability) disease activity. Similar treatment target achievement rates were observed in the subgroup with ≥ 1 extraarticular PsA manifestation (n = 126; ModDA: 66.7%, HDA: 32.2%).Conclusion.Apremilast-treated patients with baseline ModDA had higher probability of achieving cDAPSA treatment targets than patients with HDA. Resolution and/or near resolution of articular and/or extraarticular PsA manifestations was achieved by patients in REM/LDA at week 52. Consistent treatment target achievement was observed in patients with 1 or multiple extraarticular manifestations of active PsA.
Mortality Rates in Patients With Ankylosing Spondylitis With and Without Extraarticular Manifestations and Comorbidities: A Retrospective Cohort Study
Authors: Kelty Erin , Ognjenovic Milica , Raymond Warren D. , Inderjeeth Charles A. , Keen Helen I. , Preen David B. , Nossent Johannes C. 
Published: April 2022

Objective.To examine mortality rates in hospitalized patients with ankylosing spondylitis (AS) and the association of extraarticular manifestations (EAMs) and comorbidities with mortality rates.Methods.This study was a retrospective, population-based cohort study using linked administrative data from patients with AS who were hospitalized (n = 1791) and patients in a matched comparison group (n = 8955). Mortality data for patients were obtained from the Western Australia Death Register. The presence of EAMs and comorbidities was identified from hospital records. Mortality rates were compared between the 2 groups using Cox proportional hazard models overall and stratified by a history of EAMs, comorbidities, and smoking status.Results.Crude mortality rates were significantly higher among patients with AS than among patients in the comparison group (hazard ratio [HR] 1.85, 95% CI 1.62–2.12), with excess mortality in the AS group associated with cardiovascular disease (CVD; HR 5.32, 95% CI 3.84–7.35), cancer (HR 1.68, 95% CI 1.27–2.23), external causes (HR 3.92, 95% CI 2.28–6.77), and infectious diseases (HR 25.92, 95% CI 7.50–89.56). When patients were stratified by history of EAMs, CVD, and smoking, the risk of mortality was elevated in patients both with and without each risk factor. Among patients with AS, histories of CVD (HR 6.33, 95% CI 4.79–8.38), diabetes (HR 2.81, 95% CI 1.99–3.95), smoking (HR 1.49, 95% CI 1.18–1.89), and EAMs (HR 1.62, 95% CI 1.24–2.11) were associated with an increased risk of mortality.Conclusion.The presence of comorbidities, EAMs, and smoking contributes to an increased risk of all-cause mortality among patients with AS who are hospitalized compared to patients in the comparison group. These results support the need to prevent or reduce the occurrence of comorbidities and smoking in patients with AS.
Secukinumab in United States Biologic-Naïve Patients With Psoriatic Arthritis: Results From the Randomized, Placebo-Controlled CHOICE Study
Authors: Nguyen Tien , Churchill Melvin , Levin Robert , Valenzuela Guillermo , Merola Joseph F. , Ogdie Alexis , Orbai Ana-Maria , Scher Jose U. , Kavanaugh Arthur , Kianifard Farid , Rollins Chauncy , Calheiros Renato , Chambenoit Olivier 
Published: April 2022

ObjectiveTo evaluate secukinumab (SEC) 300 mg and 150 mg vs placebo in a United States–only population of biologic-naïve patients with psoriatic arthritis (PsA).MethodsCHOICE was a double-blind, randomized controlled trial conducted in the US. Biologic-naïve patients with PsA and psoriasis (PsO) were randomized 2:2:1 to SEC 300 mg (n = 103), SEC 150 mg (n = 103), or placebo (n = 52). The primary objective was to show superiority of SEC 300 mg vs placebo in American College of Rheumatology 20% (ACR20) response at week 16. Additional objectives included the effect of SEC on dactylitis, enthesitis, PsO, and safety.ResultsACR20 response rates at week 16 were higher with SEC 300 mg than with placebo (51.5% vs 23.1%; odds ratio 3.51 [95% CI 1.65-7.45]; P = 0.001). SEC 300 mg also led to greater ACR50/70 responses and improvements in other variables vs placebo. Responses were generally sustained over time. Patients with inadequate response to SEC 150 mg at weeks 16, 28, or 40 who received dose escalation to 300 mg experienced improved clinical response after uptitration. The most common adverse events were upper respiratory tract infections and diarrhea. No inflammatory bowel disease was reported or new safety signals observed.ConclusionSEC 300 mg led to rapid and significant improvements over placebo in symptoms of PsA in this heavier population of US-only, biologic-naïve patients. Findings were consistent with previous studies and suggest that SEC 300 mg is a safe and efficacious first-line biologic treatment for patients with PsA. [ClinicalTrials.gov: NCT02798211]
Whole-Body Macrophage Positron Emission Tomography Imaging for Disease Activity Assessment in Early Rheumatoid Arthritis
Authors: Verweij Nicki J.F. , de Jongh Jerney , Wee Marieke M. ter , Zwezerijnen Gerben J.C. , Yaqub Maqsood , Voskuyl Alexandre E. , Lammertsma Adriaan A. , van Schaardenburg Dirkjan , Boers Maarten , Lems Willem F. , van der Laken Conny J. 
Published: April 2022

ObjectiveTo investigate the potential of whole-body positron emission tomography/computed tomography (PET/CT) with a macrophage tracer to image arthritis in patients with early rheumatoid arthritis (RA).MethodsThirty-five previously untreated, clinically active patients with early RA underwent whole-body PET/CT scanning with the macrophage tracer (R)-[11C]PK11195 in addition to clinical assessment (Disease Activity Score in 44 joints [DAS44]). Tracer uptake was assessed quantitatively as standardized uptake values (SUVs). In addition, 2 readers blinded to clinical assessment visually scored tracer uptake in joints. Clinical and PET variables were compared using Cohen , linear regression/correlation, and t tests, where appropriate.ResultsAll but 1 patient showed enhanced tracer uptake in at least 1 joint. Twelve percent of all joints (171/1470) were visually positive on the PET scan, most frequently the small joints in feet (40%) and hands (37%), followed by wrists (15%). Correlations of visual scores with clinical findings both at patient and joint levels were absent or weak. In contrast, average SUVs in the hands, feet, and whole body showed significant correlations with DAS44 scores, with the best correlation seen in the feet (R2 = 0.29, P < 0.01).ConclusionClinically active patients with early RA had increased joint uptake of a macrophage PET tracer, especially in the feet. Quantitative, but not visual PET measures of whole body and joint groups, particularly the feet, showed moderate and statistically significant correlations with clinical outcome.
Potential Impact of Sex and BMI on Response to Therapy in Psoriatic Arthritis: Post Hoc Analysis of Results From the SEAM-PsA Trial
Authors: Mease Philip J. , Gladman Dafna D. , Merola Joseph F. , Deodhar Atul , Ogdie Alexis , Collier David H. , Liu Lyrica , Kavanaugh Arthur 
Published: April 2022

ObjectiveIn this post hoc analysis, we examined the potential impact of sex and BMI on response in the Study of Etanercept and Methotrexate in Combination or as Monotherapy in Subjects with Psoriatic Arthritis (SEAM-PsA) trial (NCT02376790), a 48-week, phase III, randomized controlled trial that compared outcomes with methotrexate (MTX) monotherapy, etanercept (ETN) monotherapy, and MTX+ETN combination therapy in patients with psoriatic arthritis (PsA) who were naïve to MTX and biologics.MethodsWe evaluated key outcomes at week 24 stratified by sex (male vs female) and BMI (kg/m2; ≤ 30 vs > 30), including the American College of Rheumatology 20 (ACR20) criteria, minimal disease activity (MDA), very low disease activity (VLDA), and Psoriatic Arthritis Disease Activity Score (PASDAS). We analyzed data using descriptive statistics, normal approximation, logistic model, and analysis of covariance.ResultsA total of 851 patients completed the SEAM-PsA trial. Higher proportions of men than women who received MTX+ETN combination therapy achieved ACR20 (71.5% vs 58.3%;P= 0.02), MDA (45.8% vs 25.2%;P= 0.0003), and VLDA (19.1% vs 9.5%;P= 0.03), and men achieved better PASDAS (-3.0 vs -2.3;P= 0.0004). Patients with BMI ≤ 30 generally had better outcomes than those with BMI > 30 in some treatment arms for ACR20, MDA, VLDA, and PASDAS; however, there was no consistent pattern regarding the treatment arm in which the difference occurred.ConclusionImproved outcomes were observed more in men than in women for MDA and PASDAS with MTX+ETN combination therapy. Patients with BMI ≤ 30 had better outcomes than those with BMI > 30, with no clear pattern regarding treatment received. These findings suggest that contextual factors such as sex and BMI may affect response to PsA therapy.
Incidence Rates of Psoriasis in Children With Inflammatory Bowel Disease and Juvenile Arthritis Treated With Tumor Necrosis Factor Inhibitors and Disease-Modifying Antirheumatic Drugs
Authors: Baggett Katelyn , Brandon Timothy G. , Xiao Rui , Valenzuela Zachary , Buckley Lisa H. , Weiss Pamela F. 
Published: April 2022

ObjectiveTo estimate the differential effect of tumor necrosis factor inhibitor (TNFi) therapies and presence or absence of conventional synthetic disease-modifying antirheumatic drugs (DMARDs) on the incidence of psoriasis (PsO) in children with inflammatory bowel disease (IBD), juvenile idiopathic arthritis (JIA), and chronic nonbacterial osteomyelitis (CNO).MethodsThis was a retrospective cohort study from 2008 to 2020. TNFi and DMARD exposures were dichotomized as ever/never. The primary outcome was incident PsO. Incidence rates (IRs) of PsO were stratified by underlying diagnosis, TNFi agent, and DMARD use. Poisson regression was used to assess the IR ratios (IRRs) between exposure groups.ResultsThere were 5088 children who met the inclusion criteria: 3794 (75%) had IBD, 1189 (23%) had JIA, and 105 (2%) had CNO. Of the 2023 children with TNFi exposure, 613 (30%) and 1410 (70%) were with or without a DMARD, respectively. When controlling for DMARD, sex, and family history of PsO, the IRR of developing PsO in patients exposed to adalimumab (ADA) was 2.70 times higher (95% CI 1.53-4.75; P < 0.001) than those who did not receive any TNFi treatment. IRR was lower, but not significantly different, for patients exposed to infliximab (IFX; IRR 2.34, 95% CI 1.56-3.51; P < 0.001) and etanercept (ETN; IRR 2.21; 95% CI 1.17-4.21; P = 0.006) compared to TNFi-unexposed patients. IRR of TNFi exposure was lower by 0.25 (P < 0.001) in DMARD-exposed patients compared to non–DMARD-exposed patients.ConclusionIRR of TNFi-induced PsO was not significantly different among ADA, IFX, and ETN. However, for patients with exposure to any of the TNFi evaluated, the IRR was significantly lower in those also exposed to a DMARD.
Rho Kinase Expression in Giant Cell Arteritis: Validating Phosphorylated Ezrin/Radixin/Moesin Intensity Score to Increase Sensitivity of Temporal Artery Biopsy
Authors: Lally Lindsay , Narula Navneet , Goodfellow Nicola , Luqmani Raashid , Pisapia David , Spiera Robert F. 
Published: April 2022

ObjectiveAberrant Rho-associated protein kinase (ROCK) activity is implicated in several vascular and immunologic disorders. We previously demonstrated increased ROCK activity in histopathologically negative temporal artery biopsies (TABs) in subjects with clinical giant cell arteritis (GCA) compared to those without GCA. This current study aimed to examine ROCK activity in a larger cohort of biopsy-negative GCA subjects and to validate the prior findings.Methods.Based on clinical data 6 months after TAB, subjects were categorized into 2 groups: biopsy-negative GCA and controls without GCA. Paraffin-embedded TABs were stained for phosphorylated ezrin/radixin/ moesin (pERM), a surrogate of ROCK activity, and scored by 2 pathologists blinded to clinical diagnosis using a previously derived scoring system measuring staining intensity in 3 areas of the vessel.Results.Thirty-six subjects with biopsy-negative GCA and 43 controls were analyzed. The mean (SD) pERM intensity score in non-GCA subjects was 3.9 (1.4), compared to 5.0 (1.4) in those with GCA (P = 0.002). Using the predetermined cut-off of 4 to define high pERM intensity, subjects with GCA were significantly more likely to have a high pERM intensity score compared to non-GCA (odds ratio 3.67, 95% CI 1.19-11.36; P = 0.02. The sensitivity of high pERM intensity score for diagnosis of GCA in histologically negative TABs was 86% (95% CI 70-95).Conclusion.In this well-characterized cohort, those with biopsy-negative GCA had significantly higher pERM intensity scores compared to subjects without GCA. pERM staining has diagnostic significance in enhancing the sensitivity of TAB and may help to define the clinically important group of biopsy-negative GCA.
Gout and Hospital Admission for Ambulatory Care–Sensitive Conditions: Risks and Trajectories
Authors: Kiadaliri Ali , Neogi Tuhina , Englund Martin 
Published: April 2022

Objective.To investigate the risks and trajectories of hospital admission for ambulatory care–sensitive conditions (ACSCs) in gout.Methods.Among individuals aged 35 years to 85 years residing in Skåne, Sweden, in 2005, those with no doctor-diagnosed gout during 1998 to 2005 (n = 576,659) were followed from January 1, 2006, until a hospital admission for an ACSC, death, relocation outside Skåne, or December 31, 2016. Treating a new gout diagnosis (International Classification of Diseases, 10th revision, code M10) as a time-varying exposure, we used Cox proportional and additive hazard models to estimate the effects of gout on hospital admissions for ACSCs. We investigated the trajectory of hospital admissions for ACSCs from 3 years before to 3 years after gout diagnosis using generalized estimating equations and group-based trajectory modeling in an age-and sex-matched cohort study.Results.Gout was associated with a 41% increased rate of hospital admission for ACSCs (hazard ratio 1.41, 95% CI 1.35-1.47), corresponding to 121 (95% CI 104-138) more hospital admissions for ACSCs per 10,000 person-years compared with those without gout. Our trajectory analysis showed that higher rates of hospital admission for ACSCs among persons with gout were observed from 3 years before to 3 years after diagnosis, with the highest prevalence rate ratio (2.22, 95% CI 1.92-2.53) at the 3-month period after diagnosis. We identified 3 classes with distinct trajectories of hospital admissions for ACSCs among patients with gout: almost none (88.5%), low-rising (9.7%), and moderate-sharply rising (1.8%). The Charlson Comorbidity Index was the most important predictor of trajectory class membership.Conclusion.Increased risk of hospital admissions for ACSCs in gout highlights the need for better management of the disease through outpatient care, especially among foreign-born, older patients with comorbidities.
De l’utilité des objets flottants dans le cadre d’un dispositif « groupe fratrie » destiné à des frères et sœurs d’enfants porteurs de troubles du spectre de l’autisme
Authors: Claudel-Valentin Stéphanie , Jehenne Anne-Bérengère , Gagnard Marie-Line , Arnould Delphine 
Published: April 2022

Dans une perspective combinant approche systémique et psychodynamique de manière complémentaire, cet article présente une étude portant sur le vécu des frères et sœurs d’enfants porteurs de troubles du spectre de l’autisme. Afin de répondre à leurs besoins spécifiques, un dispositif nommé « groupe fratrie » a été mis en place durant 3 ans dans le cadre d’un Centre Ressources Autisme. Comprenant deux groupes d’âges d’enfants de 5 à 11 ans et d’adolescents âgés de 12 à 17 ans, il a été coanimé par deux psychologues cliniciennes. Au fil des séances et à l’aide de supervisions réalisées dans le cadre d’une recherche action, des objets flottants ont été proposés pour créer une dynamique de groupe et ainsi permettre aux enfants / adolescents d’élaborer et d’exprimer plus aisément leurs émotions et leurs difficultés. Cette étude est ponctuée par une vignette clinique, dans laquelle est décrite la construction, la mise en scène et les répercussions d’un objet flottant adapté à cette population.